| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/22/2007 | CA2622867A1 Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor |
| 03/22/2007 | CA2622725A1 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase |
| 03/22/2007 | CA2622722A1 Lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives with improved solubility |
| 03/22/2007 | CA2622721A1 Method and means of preventing and treating sleep disordered breathing |
| 03/22/2007 | CA2622616A1 Collagen receptor i-domain binding modulators |
| 03/22/2007 | CA2622614A1 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase |
| 03/22/2007 | CA2622608A1 Dipeptidyl peptidase inhibitors for treating diabetes |
| 03/22/2007 | CA2622605A1 Heterocycle compound, and production process and application thereof |
| 03/22/2007 | CA2622597A1 Histamine h3 agonist for use as therapeutic agent for lipid/glucose metabolic disorder |
| 03/22/2007 | CA2622574A1 Methods of modulating neurotrophin-mediated activity |
| 03/22/2007 | CA2622571A1 Methods of modulating neurotrophin-mediated activity |
| 03/22/2007 | CA2622558A1 Combination therapy for controlled carbohydrate digestion |
| 03/22/2007 | CA2622518A1 Thiazolinones and oxazolinones and their use as ptp1b inhibitors |
| 03/22/2007 | CA2622502A1 Use of c3-c10 17alfa-esters of 9,11-dehydrocortexolone as anti-gonadotrophic agents |
| 03/22/2007 | CA2622472A1 Dipeptidyl peptidase inhibitors for treating diabetes |
| 03/22/2007 | CA2622468A1 Composition comprising at least one naphthoic acid derivative and at least one compound of polyurethane polymer type or derivatives thereof, preparation processes therefor and uses thereof |
| 03/22/2007 | CA2622375A1 Alcanoic acid amides substituted by saturated o-heterocycles |
| 03/22/2007 | CA2622372A1 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity |
| 03/22/2007 | CA2622368A1 Liposomes for treatment of multiple myeloma |
| 03/22/2007 | CA2622322A1 Bisphosphonate formulation |
| 03/22/2007 | CA2622242A1 Inhibition of viral gene expression using small interfering rna |
| 03/22/2007 | CA2622222A1 Therapeutic pyrrolidines |
| 03/22/2007 | CA2622200A1 Nanoparticulate tadalafil formulations |
| 03/22/2007 | CA2622082A1 5-amino-4-hydroxy-7- (imidazo [1,2-a] pyridin-6- ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension |
| 03/22/2007 | CA2622021A1 Composition comprising a dendrimer and the use thereof for binding phosphate |
| 03/22/2007 | CA2621983A1 Azafused cyclin dependent kinase inhibitors |
| 03/22/2007 | CA2621949A1 Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| 03/22/2007 | CA2621830A1 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives |
| 03/22/2007 | CA2621817A1 Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics |
| 03/22/2007 | CA2621441A1 Compositions and methods for the diagnosis and therapy of bcl2-associated cancers |
| 03/22/2007 | CA2621408A1 1,2-diarylimidazoles for use as cb1 modulators |
| 03/22/2007 | CA2621399A1 Combinations comprising a vegf receptor inhibitor and a penetration enhancer |
| 03/22/2007 | CA2621370A1 Salicylate and gentisate salts of a piperazine compound |
| 03/22/2007 | CA2621368A1 Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
| 03/22/2007 | CA2621364A1 Biphenyl derivatives and their use in treating hepatitis c |
| 03/22/2007 | CA2621363A1 Methods and compositions for modulating tumor cell activity |
| 03/22/2007 | CA2621292A1 1-2-dihydroquinoline derivative having glucocorticoid receptor binding actvity |
| 03/22/2007 | CA2621273A1 Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| 03/22/2007 | CA2621270A1 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation |
| 03/22/2007 | CA2621266A1 Sustained-release formulation comprising a glucuronate salt of a piperazine compound and uses thereof |
| 03/22/2007 | CA2620923A1 Inhibition of intermediate-conductance calcium activated potassium channels in the treatment and/or prevention of atherosclerosis |
| 03/22/2007 | CA2620755A1 Glucuronate salt of a piperazine compound |
| 03/22/2007 | CA2620370A1 Extended release pharmaceutical composition of metformin and a process for producing it |
| 03/22/2007 | CA2620296A1 Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects |
| 03/22/2007 | CA2619955A1 Process for preparing valsartan |
| 03/22/2007 | CA2619073A1 Use of tellurium compounds for protection from ultra-violet radiation |
| 03/22/2007 | CA2618429A1 A hepatitis c virus non-structural ns3/4a fusion gene |
| 03/22/2007 | CA2617394A1 2-aniline-4-aryl substituted thiazole derivatives |
| 03/22/2007 | CA2616237A1 Methods of treating nervous disorders |
| 03/22/2007 | CA2612769A1 Improved pharmaceutical composition containing hmg-coa reductase inhibitor and method for the preparation thereof |
| 03/22/2007 | CA2606727A1 Lipid a analogs for treating oral and gastrointestinal mucositis |
| 03/21/2007 | EP1764370A2 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 |
| 03/21/2007 | EP1764368A1 Antimitotic halogenated derivatives of Vinca alkaloids |
| 03/21/2007 | EP1764367A1 Thienopyridine derivatives |
| 03/21/2007 | EP1764366A2 Thrombin receptor antagonists |
| 03/21/2007 | EP1764363A2 Substituted acetophenonederivatives |
| 03/21/2007 | EP1764362A1 Biaryl derivatives |
| 03/21/2007 | EP1764358A2 Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain |
| 03/21/2007 | EP1764357A1 Selective androgen receptor modulators and methods of use thereof |
| 03/21/2007 | EP1764134A2 Tetrahydroindolone and purine derivatives linked to arylpiperazines |
| 03/21/2007 | EP1764120A1 Coatings for medical devices |
| 03/21/2007 | EP1764111A1 Vaginally administered anti-dysrhythmic agents for treating pelvic pain and infertility |
| 03/21/2007 | EP1764110A1 Compositions comprising an insulin sensitivity enhancer and a biguanide |
| 03/21/2007 | EP1764104A1 Wound healing pharmaceutical composition comprising sucralfate, aluminium acetate and vitamins |
| 03/21/2007 | EP1764103A2 Crystalline amifostine compositions and methods for the preparation and use of same |
| 03/21/2007 | EP1764102A1 Quinolone-containing medicinal composition |
| 03/21/2007 | EP1764101A1 Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments |
| 03/21/2007 | EP1764099A2 Diaminoalcohol derivatives for the treatment of Alzheimer, malaria, HIV |
| 03/21/2007 | EP1764098A1 Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV |
| 03/21/2007 | EP1764097A1 Methods and compositions for soothing oral and nasal tissues |
| 03/21/2007 | EP1764096A1 Novel phloroglucinol derivatives having selectin ligand activity |
| 03/21/2007 | EP1764095A1 Novel nitrocatechol derivatives having selectin ligand activity |
| 03/21/2007 | EP1764094A1 Novel multi-cyclic compounds and their use |
| 03/21/2007 | EP1764093A1 Novel aromatic compounds and their use in medical applications |
| 03/21/2007 | EP1764092A2 Selecting compounds for treatment of Alzheimer's disease |
| 03/21/2007 | EP1764088A1 Thixotropic personal lubricant containing carageenan |
| 03/21/2007 | EP1764075A1 Tissue factor production inhibitor |
| 03/21/2007 | EP1763534A1 NOVEL 2-SUBSTITUTED D-HOMO-ESTRA-1,3,5(10)-TRIENES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 |
| 03/21/2007 | EP1763533A2 Specific antagonist for both e- and p-selectins |
| 03/21/2007 | EP1763531A1 Hepatitis c inhibitor peptide analogs |
| 03/21/2007 | EP1763530A1 Imidazopyridazine diones, the production thereof, and the use of the same as a medicament |
| 03/21/2007 | EP1763528A1 Pyrazolopyridine derivatives |
| 03/21/2007 | EP1763527A1 4-substituted quinoline derivatives, method and intermediates for preparing same and pharmaceutical compositions containing same |
| 03/21/2007 | EP1763526A1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors |
| 03/21/2007 | EP1763525A2 Stable micronized candesartan cilexetil and methods for preparing thereof |
| 03/21/2007 | EP1763524A1 Indole derivatives and use thereof as kinase inhibitors |
| 03/21/2007 | EP1763523A1 Quinazolinedione derivatives as parp inhibitors |
| 03/21/2007 | EP1763522A1 Pyridin-2-one compounds and their use as modulators of the dopamine d3 receptor |
| 03/21/2007 | EP1763521A1 1- (indole-6-carbonyl-d-phenylglycinyl)-4- (l-methylpiperidin-4- yl) piperazine d-tartrate |
| 03/21/2007 | EP1763518A1 Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
| 03/21/2007 | EP1763517A2 Pyrimidine derivatives as 11beta-hsd1 inhibitors |
| 03/21/2007 | EP1763516A2 Substituted tetrahydroisochinolines used in the form of mmp inhibitors, method for the production and use thereof in the form of drags |
| 03/21/2007 | EP1763515A1 4-trifluoromethoxyphenoxybenzol-4'-sulfonic acids, method for the production and use thereof in medicaments |
| 03/21/2007 | EP1763514A2 Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| 03/21/2007 | EP1763511A1 Phenoxyacetic acid derivatives as ppar agonists |
| 03/21/2007 | EP1763509A1 Alpha-helical mimetics |
| 03/21/2007 | EP1763507A2 Alpha-amino acid derivates with antiinflammatory activity |
| 03/21/2007 | EP1763502A1 Novel hexafluoroisopropanol derivatives |
| 03/21/2007 | EP1763500A1 Novel angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
| 03/21/2007 | EP1763370A1 Formulations comprising a capsaicinoid, a local anesthetic and/or an antipruritic agent for the treatment of pain |